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In this issue of EBioMedicine, Premer et al. report their study titled vascularize the damage heart muscle. In addition, the emphasis on the
“Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in
Heart Failure by Stimulating Endothelial Progenitor Cells” (Premer
et al., 2015). They recruited a cohort of heart failure patients from two
ongoing clinical trials evaluating both autologous and allogeneicmesen-
chymal stem cell therapies and evaluated bothmolecular and functional
markers of endothelial progenitor cell activity, showing signiﬁcantly
different outcomes between the allogeneic MSC recipients and the au-
tologous MSC recipients. Mechanistically, Premer et al. show that
MSCs can improveﬂowmediated vasodilation in their cohorts of patient
while reducing the circulating VEGF to normal levels and increasing cir-
culating endothelial progenitors.
Mesenchymal Stem Cells (MSCs) were ﬁrst reported by Friedenstein
et al. in 1970 (Friedenstein et al., 1970). The ﬁnding that these cells
could be induced to undergo cardiomyogenesis (Li et al., 2007; Xu
et al., 2004) stimulated great excitement regarding their cardiac regen-
erative capacity as a treatment for ischemic cardiomyopathy, and more
recently for dilated cardiomyopathy. In fact, it could be argued that
these discoveries catalyzed the proliferation of reports exploring the
beneﬁts of cell therapies, in-vitro, in animal models of heart failure
and in clinical trials. This effect on the biomedical community can be il-
lustrated by Fig. 1, which shows results from PubMed and Grants.gov
searches several key words. While these searches are not exhaustive,
it clearly shows that we have experienced a rapid growing interest in
the potential of stem cells to 1.) improve clinical outcomes for heart
failure patients, 2.) improve cardiac performance and reverse cardiac re-
modeling in these patients and 3.) regenerate lost myocardium, espe-
cially cardiomyocytes. Our ability to show each of these effects is
relatively diverse. While testing for improved clinical outcomes with
quality of life, imaging and hemodynamic endpoints is relatively
straightforward, the degree of cardiac regeneration has been very chal-
lenging and inconsistent. Furthermore, the optimistic outcomes report-
ed in pre-clinical studies have not been realized in clinical trials. This is
partially due to the undetermined mechanism of action at the molecu-
lar, cellular and organ levels. As we have progressed through the ﬁrst
decade and a half of MCS cell therapy studies, their safety has been
clearly demonstrated and the use of allogeneic vs autologous sources
are being explored in detail (Karantalis et al., 2015). It is becoming
increasingly clear that several progenitor cell types including MSCs re-DOI of original article: http://dx.doi.org/10.1016/j.ebiom.2015.03.020.
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2011; Centola et al., 2008; Champion and Hare, 2001) is emerging as a
likely mode of action. From the more classical viewpoint, this involves
cellular (such as MSCs) release of factors, including small proteins and
growth factors, to either neighboring or remote cell types. These factors
can be ligands of key receptor tyrosine kinases including vascular endo-
thelial growth factor (VEGF) that bind to cell surface receptors such as
VEGF receptors on endothelial cells.
The cohort of patients in this study was recruited from the
TRansendocardial Stem Cell Injection Delivery Effects on Neomyogenesis
STudy (TRIDENT) in ischemic cardiomyopathy patients as well as the
PercutaneOus StEm Cell Injection Delivery Effects on Neomyogenesis
in Dilated CardioMyopathy (POSEIDON-DM) study. While data are
available from the POSEIDON-PILOT study (Hare et al., 2012) evaluating
a cohort of patients with ischemic cardiomyopathy, the POSEIDON-DCM
and TRIDENT study results are not yet available. In the POSEIDON-PILOT
study, no signiﬁcantly different outcomes were noted between allogenic
and autologous MSC recipients. It should be noted that there was no
placebo control in the POSEIDON-PILOT study, so efﬁcacy cannot be rig-
orously tested.
MSCs have been reported to be immunoprivileged and immunosup-
pressive, because they do not express major histocompatibility class II
antigens and they secrete T helper type 2 cytokines (Hare et al., 2012).
Therefore, the potential beneﬁts of allogenic cell include use as an
“off-the-shelf” therapeutic, thus avoiding the necessity for additional
procedures for patients and delays in therapy. In addition, cell quality
and selection could be much more highly controlled. There are also
some concerns that autologous MSCs could be impaired in patients
with comorbidities or advanced age.
On a functional level, the percent ﬂow mediated brachial artery va-
sodilation was impaired in HF patients relative to healthy controls. It
should be noted that the healthy controls are younger than the patient
cohorts, but the implications of this difference is not clear. At the cellular
level, EPC-colony forming units (EPC-CFUs) isolated from peripheral
blood were markedly reduced in HF patients compared to the healthy
controls. At the molecular level, patients had elevated circulating
(VEGF). Thus, based on these results, it was concluded that the heart
failure patients suffered from endothelial dysfunction.
In order to understand the potential impact of MSCs to endothelial
function, cultured medium from both autologous and allogeneic MSC
cultureswere introduced to HUVEC culturedwith vasculogenesis inhib-
itors to evaluate the role of the MSC secretome in repair of endothelial
dysfunction. The outcomes from these studies suggest that in contrastthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. PubMed Citations using “heart failure” and either “stem cell”, “mesenchymal”,
“mesenchymal or bone marrow”, “cardiac progenitor”, or “cardiosphere”. Inset: citations
in Clinical Trials.gov using “heart failure” and “cell therapy”.
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that overcame the inhibitory effects and could restore endothelial pro-
genitor cell function and vasculogenesis.
Functional, cellular andmolecular parameters in the patient popula-
tion were compared at baseline and three months post-treatment. The
allogeneicMSC recipient endpoints improvedwhile autologousMSC re-
cipients did not. These outcomes included ﬂow mediated vasodilation,
increased propensity of circulating endothelial progenitors to form
colonies, in-vitro, and MSC mediated decreased circulating VEGF.
Perhaps most convincing, are the correlations between functional,
cellular and molecular endpoints. Namely, there is a strong correlation
between increases in FMD% or decreases in VEGF with concomitant in-
creases in EPC-CFUs.
Based on the results in this paper, it was concluded that allogeneic
MSCs resulted in more optimistic outcomes for patients with DCM and
ICM partially resulting from corrected endothelial function. There ap-
pears to be MSC produced soluble mediators that may be released into
the extracellular matrix which correct the endothelial progenitor dys-
function, comorbidity in the cohort of patients studied. Since VEGF stim-
ulates endothelial repair, it is somewhat surprising that allogenic MSCs
drive the circulating VEGF level in these patients down,which results in
improved vasculogenesis, and is inversely related to the population of
circulating endothelial progenitors and with FMD. Therefore there is a
need for further study to determine the exact cellular and molecular
basis by which MSCs exert these effects via their secretome. There
are some limitations that could be addressed in subsequent studies fo-
cusing on determining how the MSC secretome impacts endothelial
progenitor dysfunction in heart failure patient. In order to unequivocally
demonstrate that allogeneic MSC therapy has a positive effect on endo-
thelial progenitor cell dysfunction in heart failure patients, a double-blinded study that includes placebo controls is necessary. In addition,
there should be complete proﬁling of the allogeneic MSCs used in
these studies, and they should be from individual as opposed to pooled
sources to demonstrate how general this effect is as well as its clinical
signiﬁcance. In addition, while the parent clinical trials are still ongoing,
it will be important to correlate the molecular, cellular and functional
outcomes reported by Premer et al. to cardiac function and quality of
life endpoints. Finally, while extremely challenging, understanding the
fate of deliveredMSCs is critically important to understanding their clin-
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